JP2020505386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505386A5 JP2020505386A5 JP2019539905A JP2019539905A JP2020505386A5 JP 2020505386 A5 JP2020505386 A5 JP 2020505386A5 JP 2019539905 A JP2019539905 A JP 2019539905A JP 2019539905 A JP2019539905 A JP 2019539905A JP 2020505386 A5 JP2020505386 A5 JP 2020505386A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- antibody
- fragment
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 46
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 206010034674 peritonitis Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010014824 Endotoxic shock Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
- 206010021263 IgA nephropathy Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000027530 Meniere disease Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 3
- 208000031737 Tissue Adhesions Diseases 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 210000000941 bile Anatomy 0.000 claims description 3
- 230000024279 bone resorption Effects 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 230000015271 coagulation Effects 0.000 claims description 3
- 238000005345 coagulation Methods 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 206010014599 encephalitis Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 230000003325 follicular Effects 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 230000000796 hypoacidity effect Effects 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- 208000000509 infertility Diseases 0.000 claims description 3
- 230000036512 infertility Effects 0.000 claims description 3
- 231100000535 infertility Toxicity 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 208000023589 ischemic disease Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 239000004571 lime Substances 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 238000007792 addition Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 208000024386 fungal infectious disease Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076092A JP2023100824A (ja) | 2017-01-20 | 2023-05-02 | 抗ｐｄ－１抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710046148 | 2017-01-20 | ||
| CN201710046148.2 | 2017-01-20 | ||
| PCT/CN2018/073383 WO2018133837A1 (en) | 2017-01-20 | 2018-01-19 | Anti-pd-1 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076092A Division JP2023100824A (ja) | 2017-01-20 | 2023-05-02 | 抗ｐｄ－１抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505386A JP2020505386A (ja) | 2020-02-20 |
| JP2020505386A5 true JP2020505386A5 (cg-RX-API-DMAC7.html) | 2021-03-04 |
| JP7275030B2 JP7275030B2 (ja) | 2023-05-17 |
Family
ID=62907770
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539905A Active JP7275030B2 (ja) | 2017-01-20 | 2018-01-19 | 抗ｐｄ－１抗体およびその使用 |
| JP2023076092A Pending JP2023100824A (ja) | 2017-01-20 | 2023-05-02 | 抗ｐｄ－１抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076092A Pending JP2023100824A (ja) | 2017-01-20 | 2023-05-02 | 抗ｐｄ－１抗体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10465007B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3571231A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7275030B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102536145B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN110382536B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018209556C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019013238A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3049047A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019007848A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI771361B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2018133837A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI771361B (zh) | 2017-01-20 | 2022-07-21 | 大陸商大有華夏生物醫藥集團有限公司 | 人程序性死亡受體pd-1的單株抗體及其片段 |
| TWI806870B (zh) * | 2018-05-23 | 2023-07-01 | 中國大陸商大有華夏生物醫藥集團有限公司 | 抗pd-1抗體及其用途 |
| WO2019227490A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| JP2021525806A (ja) | 2018-06-01 | 2021-09-27 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | 疾患または状態を処置するための組成物およびそれらの使用 |
| JP7519985B2 (ja) | 2018-07-19 | 2024-07-22 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | 抗ｐｄ－１抗体、投薬量、およびその使用 |
| CN110845614A (zh) * | 2018-08-21 | 2020-02-28 | 大有华夏生物医药集团有限公司 | 人细胞表面免疫调节分子 |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| CN111253486B (zh) * | 2018-09-27 | 2023-09-29 | 再鼎医药(上海)有限公司 | 抗pd-1抗体及其用途 |
| CA3124660A1 (en) * | 2018-12-21 | 2020-06-25 | Gloriana Therapeutics Sarl | Mammalian cell culture-produced neublastin antibodies |
| US12263234B2 (en) | 2019-01-23 | 2025-04-01 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Anti-PD-L1 diabodies and the use thereof |
| WO2020156509A1 (zh) * | 2019-02-03 | 2020-08-06 | 江苏恒瑞医药股份有限公司 | 抗pd-1抗体、其抗原结合片段及医药用途 |
| WO2021004480A1 (zh) * | 2019-07-08 | 2021-01-14 | 南京金斯瑞生物科技有限公司 | 抗cd47/抗pd-1双特异抗体及其制备方法和应用 |
| WO2021043261A1 (zh) * | 2019-09-06 | 2021-03-11 | 北京拓界生物医药科技有限公司 | 抗pd-1单域抗体、其衍生蛋白及其医药用途 |
| JP2023520772A (ja) * | 2020-03-26 | 2023-05-19 | キュアイミューン セラピューティクス インク． | 抗ｐｄ－１抗体及び使用の方法 |
| TWI859446B (zh) * | 2020-05-26 | 2024-10-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-pd-1抗體 |
| US20230235075A1 (en) | 2020-06-02 | 2023-07-27 | Dynamicure Biotechnology Llc | Anti-cd93 constructs and uses thereof |
| CN116529260A (zh) | 2020-06-02 | 2023-08-01 | 当康生物技术有限责任公司 | 抗cd93构建体及其用途 |
| AU2021315665A1 (en) | 2020-07-29 | 2023-03-16 | Dynamicure Biotechnology Llc | Anti-CD93 constructs and uses thereof |
| CN116782937A (zh) * | 2020-12-10 | 2023-09-19 | 优特力克斯有限公司 | 抗pd-1抗体及其用途 |
| JP2024511424A (ja) | 2021-03-25 | 2024-03-13 | ダイナミキュア バイオテクノロジー エルエルシー | 抗ｉｇｆｂｐ７構築物およびその使用 |
| CN115521379B (zh) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-1抗体及其用途 |
| CN116589572B (zh) * | 2023-06-28 | 2023-11-10 | 湖南诺合新生物科技有限公司 | 一种抗ha标签的单克隆抗体及其应用 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5756096A (en) | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| ATE200679T1 (de) | 1997-04-14 | 2001-05-15 | Micromet Ag | Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2290485C (en) | 1997-05-21 | 2008-08-05 | Biovation Limited | Method for the production of non-immunogenic proteins |
| AU8619698A (en) | 1997-07-25 | 1999-02-16 | Ban C. H. Tsui | Devices, systems and methods for determining proper placement of epidural catheters |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| JP4511943B2 (ja) * | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| NZ547279A (en) | 2003-10-22 | 2008-04-30 | Keck Graduate Inst | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| NZ600758A (en) * | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| WO2010029435A1 (en) * | 2008-09-12 | 2010-03-18 | Isis Innovation Limited | Pd-1 specific antibodies and uses thereof |
| HUE030807T2 (en) * | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| AU2014361473B2 (en) * | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) * | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| TR201901507T4 (tr) | 2014-02-04 | 2019-02-21 | Merck Sharp & Dohme | Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu. |
| NZ728688A (en) * | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
| AU2015355137A1 (en) | 2014-12-02 | 2017-06-08 | Celgene Corporation | Combination therapies |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| CN104479020B (zh) * | 2014-12-26 | 2019-08-02 | 上海复宏汉霖生物技术股份有限公司 | 一种抗pd-1人源抗体 |
| CN105061597B (zh) * | 2015-06-09 | 2016-04-27 | 北京东方百泰生物科技有限公司 | 一种抗pd-1的单克隆抗体及其获得方法 |
| CN106699888B (zh) | 2015-07-28 | 2020-11-06 | 上海昀怡健康科技发展有限公司 | 一种pd-1抗体及其制备方法和应用 |
| SMT202100527T1 (it) | 2015-07-30 | 2021-11-12 | Macrogenics Inc | Molecole di legame a pd-1 e lag-3 e loro metodi d'uso |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| RU2722451C1 (ru) | 2015-09-29 | 2020-06-01 | Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. | Pd-1 антитела и их применение. |
| DK3368572T3 (da) | 2015-10-02 | 2022-08-08 | Symphogen As | Anti-pd-1-antistoffer og -sammensætninger |
| CN105175544B (zh) * | 2015-10-20 | 2021-04-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-1人源化单克隆抗体及其应用 |
| CN105566496B (zh) * | 2015-11-26 | 2019-04-02 | 大庆东竺明生物技术有限公司 | 阻断人程序性死亡因子1(pd-1)功能的单克隆抗体及其编码基因和应用 |
| CN106008714B (zh) * | 2016-05-24 | 2019-03-15 | 瑞阳(苏州)生物科技有限公司 | 抗人pd-1人源化单克隆抗体及其应用 |
| US10669338B2 (en) | 2016-06-17 | 2020-06-02 | Immunomedics, Inc. | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 |
| RU2656181C1 (ru) | 2016-07-13 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Анти-pd-1-антитела, способ их получения и способ применения |
| MX2019002946A (es) | 2016-09-14 | 2019-09-26 | Abbvie Biotherapeutics Inc | Anticuerpos anti-pd-1 y sus usos. |
| CN108203464B (zh) | 2016-12-25 | 2021-07-20 | 南京金斯瑞生物科技有限公司 | 高亲和力、高特异性、多抗原识别表位的具有更高功能性的抗人pd-1抗体 |
| TWI771361B (zh) | 2017-01-20 | 2022-07-21 | 大陸商大有華夏生物醫藥集團有限公司 | 人程序性死亡受體pd-1的單株抗體及其片段 |
| JP7519985B2 (ja) * | 2018-07-19 | 2024-07-22 | タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド | 抗ｐｄ－１抗体、投薬量、およびその使用 |
-
2018
- 2018-01-19 TW TW107102117A patent/TWI771361B/zh active
- 2018-01-19 EP EP18742363.7A patent/EP3571231A4/en active Pending
- 2018-01-19 KR KR1020227005365A patent/KR102536145B1/ko active Active
- 2018-01-19 BR BR112019013238-4A patent/BR112019013238A2/pt unknown
- 2018-01-19 CN CN201880007550.2A patent/CN110382536B/zh active Active
- 2018-01-19 CN CN202311368997.1A patent/CN117586401A/zh active Pending
- 2018-01-19 CA CA3049047A patent/CA3049047A1/en active Pending
- 2018-01-19 AU AU2018209556A patent/AU2018209556C1/en active Active
- 2018-01-19 KR KR1020197018881A patent/KR102365972B1/ko active Active
- 2018-01-19 JP JP2019539905A patent/JP7275030B2/ja active Active
- 2018-01-19 WO PCT/CN2018/073383 patent/WO2018133837A1/en not_active Ceased
- 2018-01-19 MX MX2019007848A patent/MX2019007848A/es unknown
- 2018-01-19 WO PCT/CN2018/073437 patent/WO2018133842A1/zh not_active Ceased
- 2018-01-19 CN CN201880002948.7A patent/CN110291109B/zh active Active
-
2019
- 2019-01-18 US US16/252,418 patent/US10465007B2/en active Active
- 2019-08-16 US US16/543,310 patent/US11560430B2/en active Active
-
2023
- 2023-05-02 JP JP2023076092A patent/JP2023100824A/ja active Pending
- 2023-10-24 US US18/493,568 patent/US20240182579A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505386A5 (cg-RX-API-DMAC7.html) | ||
| TWI757304B (zh) | Lag-3抗體、其抗原結合片段及其醫藥用途 | |
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| TWI751979B (zh) | 抗ｇａｒｐ抗體 | |
| CN112969716B (zh) | 抗pd-1抗体、其抗原结合片段及医药用途 | |
| CN109311971A (zh) | 抗TL1A/抗TNF-α双特异性抗原结合蛋白及其用途 | |
| RU2021133819A (ru) | Анти-lag-3 антитела | |
| CN106573053B (zh) | 干扰素α和ω抗体拮抗剂 | |
| JP2015510510A5 (cg-RX-API-DMAC7.html) | ||
| JP2012500020A5 (cg-RX-API-DMAC7.html) | ||
| CN110914304A (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| JP2019522961A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537400A5 (cg-RX-API-DMAC7.html) | ||
| RU2009128064A (ru) | Антитела к cd44 | |
| RU2015143886A (ru) | Антитела к тау и способы применения | |
| JP2016538876A5 (cg-RX-API-DMAC7.html) | ||
| JP2020514277A5 (cg-RX-API-DMAC7.html) | ||
| JP2022517441A (ja) | Ｂｔｌａ抗体 | |
| JP2020511946A5 (cg-RX-API-DMAC7.html) | ||
| JP2020522280A5 (cg-RX-API-DMAC7.html) | ||
| CN104662153A (zh) | 针对转运体的抗体及其用途 | |
| JP2016520595A5 (cg-RX-API-DMAC7.html) | ||
| JP6247646B2 (ja) | ヒト化抗ｈｍｇｂ１抗体もしくはその抗原結合性断片 | |
| JP2019518473A5 (cg-RX-API-DMAC7.html) | ||
| WO2022206753A1 (zh) | GARP/TGFβ1抗体及其应用 |